抑制 c-Myc 的 Hyper-O-GlcNAcylation 通过减轻角质形成细胞功能障碍加速糖尿病伤口愈合

2022-03-04 MedSci原创 MedSci原创

这些发现使 c-Myc 和 O-GlcNAc 成为糖尿病伤口的潜在治疗靶点。

以延迟愈合为特征的糖尿病足溃疡是糖尿病的主要并发症之一。已发现表皮角质形成细胞功能障碍在糖尿病伤口愈合能力差中起关键作用。在本研究中,我们旨在探讨 c-Myc 及其 O-连接的 N-乙酰氨基葡萄糖 (O-GlcNAc) 糖基化 (O-GlcNAcylation) 修饰与糖尿病伤口中角质形成细胞功能障碍之间的关系。

图1 文章来源

研究团队采集了临床创面标本,并建立糖尿病大鼠全层皮肤缺损创面模型。采用H&E染色观察创面再上皮化,免疫组化检测增殖细胞核抗原、转谷氨酰胺酶1、loricrin、c-Myc和O-GlcNAc的表达。

观察过表达或敲低c-Myc后人永生化表皮细胞(HaCaT)细胞增殖、迁移和分化的功能变化。使用免疫沉淀和邻近连接测定证实了 c-Myc 的 O-GlcNAcylation。使用放线菌酮测量c-Myc蛋白的稳定性。

在糖尿病伤口上局部应用抑制 c-Myc 或 O-GlcNAc 的化合物后,观察到伤口愈合。

结果显示,糖尿病伤口边缘的角质形成细胞具有增殖分裂活跃、迁移缓慢、分化差的特点。

图2糖尿病患者伤口边缘的表皮角质形成细胞以增殖活跃、迁移缓慢和分化功能障碍为特征。

在糖尿病大鼠伤口边缘的 30 mM 葡萄糖和角质形成细胞中培养的 HaCaT 细胞中也观察到了类似的现象。

图3HaCaT 细胞在 30 mM 葡萄糖和大鼠糖尿病伤口边缘的角质形成细胞中培养,表现出活跃的增殖、缓慢的迁移和分化功能障碍。

c-Myc 在糖尿病大鼠、患者伤口边缘的角质形成细胞和用 30 mM 葡萄糖培养的 HaCaT 细胞中的表达增加。

c-Myc 表达增加促进增殖,同时抑制 HaCaT 细胞的迁移和分化,抑制 c-Myc 促进糖尿病伤口愈合。

图4c-Myc 促进增殖并抑制 HaCaT 细胞的迁移和分化。

用 30 mM 葡萄糖增加 c-Myc 的 O-GlcNAcylation 稳定了 c-Myc 蛋白。

抑制 O-GlcNAc 可改善角质形成细胞功能障碍并促进糖尿病伤口愈合。

图5c-Myc 的抑制促进了糖尿病伤口的愈合。

总而言之,这项研究首先评估了c-Myc O-GlcNAcylation的调节可能影响糖尿病伤口的愈合。c-Myc 表达增加促进异常增殖并抑制糖尿病伤口边缘角质形成细胞的迁移或分化。在高葡萄糖糖尿病状态下增加的 c-Myc 的 O-GlcNAcylation 稳定了 c-Myc 蛋白。抑制 c-Myc 或 O-GlcNAc 可缓解糖尿病伤口愈合延迟。

这些发现使 c-Myc 和 O-GlcNAc 成为糖尿病伤口的潜在治疗靶点。

原始文章:

Jie Zhang, Peilang Yang, Dan Liu, Min Gao, Jizhuang Wang, Tianyi Yu, Xiong Zhang, Yan Liu, Inhibiting Hyper-O-GlcNAcylation of c-Myc accelerate diabetic wound healing by alleviating keratinocyte dysfunction,Burns & Trauma, Volume 9, 2021, tkab031

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-09-18 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-02 guihongzh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-02 lixiaol
  6. [GetPortalCommentsPageByObjectIdResponse(id=1729395, encodeId=c19f1e2939538, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 04:29:10 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274859, encodeId=e63d12e48596c, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309923, encodeId=590013099230a, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421432, encodeId=bd6714214326e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530308, encodeId=bfc5153030816, content=<a href='/topic/show?id=2c9738e9d2' target=_blank style='color:#2F92EE;'>#c-myc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3879, encryptionId=2c9738e9d2, topicName=c-myc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b12082233, createdName=lixiaol, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586866, encodeId=0c6e1586866ea, content=<a href='/topic/show?id=a6d1e7821de' target=_blank style='color:#2F92EE;'>#细胞功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77821, encryptionId=a6d1e7821de, topicName=细胞功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec517387980, createdName=般若傻瓜, createdTime=Wed Mar 02 12:29:10 CST 2022, time=2022-03-02, status=1, ipAttribution=)]

相关资讯

J Am Podiatr Med Assoc:富血小板血浆治疗糖尿病足溃疡的疗效如何?

糖尿病足溃疡(DFU)可以通过控制感染、血糖正常状态和溃疡清创来得到很好的控制,然后进行适当的包扎和足部减压。研究表明,大约90%的DFU经过适当的减压休息后在近6周内痊愈。富血小板血浆(PRP)可作

Diabetes Metab Res Rev:TIR与糖尿病足溃疡住院患者的截肢和全因死亡率呈负相关

糖尿病足溃疡(DFU)是糖尿病最严重的并发症之一。常伴有较高的发病率、截肢和死亡率。糖尿病患者中DFU的终生发生率为19%~34%。

糖尿病足福音?这项手术或可提供可观经济效益!

糖尿病神经病变、足部溃疡和下肢截肢的成本已经是巨大的,据报道,除糖尿病本身的成本外,公共和私人支付人的负担从90亿美元到130亿美元不等。

多项研究显示,补这个有用,这样吃有利于糖尿病创面和溃疡愈合!

目前针对糖尿病足的营养干预研究,主要显示了补充以下维生素有利于改善创面结局。

糖尿病足创面负压创面治疗应用共识

编写组借鉴最新临床研究建议的循证实践,提出了糖尿病足 NPWT 应用和预后评估的最佳临床实践指南。该共识旨在建立支持临床医生在治疗糖尿病足病例时可以参考的标准化治疗方案。

马鲁波:膝下流出道重建在糖尿病足创面干预中的重要性

糖尿病下肢严重缺血的特点以神经缺血性溃疡为主,单纯的溃疡不缺血的病人非常少,不同文献认为50%~70%的糖尿病严重缺血患者有神经缺血性糖尿病足(DMF)。

拓展阅读

糖尿病足溃疡IDSA/IWGDF分类系统

糖尿病足有多种分级方法,包括常用Wagner、Texas、PEDIS和简易分级法,简易分级法相对简单易用。点击立即查看。

JTV:减压球对糖尿病足溃疡患者锐性清创术中疼痛和焦虑的影响

使用减压球是实用、简便、经济的非药物方法,可常规用于减轻清创术中的疼痛和焦虑。

脊髓电刺激治疗糖尿病足慢性疼痛的前景分析

本文综述了SCS技术及其在糖尿病足慢性疼痛中的临床研究,并描述了SCS的前景和当前面临的挑战。

“糖足”早期,有哪些蛛丝马迹?

广大糖尿病患者,要定期进行科学规范的足部风险筛查,提高对疾病危害的认识,才能尽量降低或者避免糖尿病足的发生。

糖尿病足溃疡创面愈合4阶段:坏死期、腐肉期、肉芽形成期与上皮形成期的敷料选择

随着科学的进步,新型的复合型敷料、功能性敷料已经或正在开发中。由于伤口具有个体化差异,因此强调个性化敷料的选择。

冬季血糖波动大!糖尿病患者如何控糖?

了解冬季糖尿病的管理要点并做出积极的调整,对于糖尿病患者来说至关重要。

2024 RNAO指南: 糖尿病足溃疡:预防、评估和管理-第三版

安大略省注册护士协会(RNAO,Registered Nurses&#039;Association of Ontario) · 2024-10-23

中国糖尿病足诊治指南(2024)

中国医疗保健国际交流促进会 · 2024-11-15

2024 EANM循证指南:糖尿病足的诊断影像学检查

欧洲核医学协会(EANM,European Association of Nuclear Medicine) · 2024-07-29